1Department of Biomedical Science, Faculty of Medicine, Universitas Prima Indonesia, Indonesia
2Faculty of Medicine, Universitas Sumatera Utara, Indonesia
3Faculty of Medicine, Universitas Prima Indonesia, Indonesia
BibTex Citation Data :
@article{JBTR17379, author = {Linda Chiuman and Dearni Anggita Krismayani Purba and Hendy Million Samin}, title = {Understanding Platelet-Rich Plasma as Potential Therapy To Improve Cardiac Function After Myocardial Infarction: Based On Evidence}, journal = {Journal of Biomedicine and Translational Research}, volume = {9}, number = {1}, year = {2023}, keywords = {Platelet-rich plasma; Myocardial Infarction; Angiogenesis; Cardiac function}, abstract = { Myocardial infarction is the leading cause of death in the world’s population. The sudden and progressive loss of cardiomyocyte contractile cells due to infarction is disproportionate to the number of new cells formation. This pathological condition will ultimately reduce the function of the heart muscles. Platelet-rich plasma (PRP) in the last decade has been attracting attention regarding its role in cell regeneration. The content of cytokines and growth factors contained in PRP such as Platelet-Derived Growth Factor (PDGF), Transforming Growth Factor Beta 1 (TGF-Β1), Epidermal Growth Factor (EGF), Vascular Endothelial Growth Factor (VEGF), Basic Fibroblast Growth Factor (bFGF) and others are known to be involved in the migration, proliferation, and differentiation of various cell types and to induce post-ischemic angiogenesis. This review aims to analyze and investigate the benefits of PRP therapy in myocardial infarction. Recent literatures regarding the use of PRP in myocardial infarction was collected by searching PubMed and Google Scholar databases with the keywords of “Platelet-rich plasma”, “Myocardial Infarction”, “Reperfusion”, and “Angiogenesis”. The researches used was published between January 2011 and December 2022. Based on the results, Platelet-rich Plasma (PRP) is considered capable of accelerating angiogenesis, mitogenesis, protect cells from free radicals, reduce infarct area and scar tissue in myocardial infarction. PRP can also improve cardiac function in post myocardial infarction by increasing ejection fraction. In addition, PRP can also reduce treatment costs due to the risk of myocardial infarction complications such as bleeding and infection. }, issn = {2503-2178}, pages = {39--46} doi = {10.14710/jbtr.v9i1.17379}, url = {https://ejournal2.undip.ac.id/index.php/jbtr/article/view/17379} }
Refworks Citation Data :
Myocardial infarction is the leading cause of death in the world’s population. The sudden and progressive loss of cardiomyocyte contractile cells due to infarction is disproportionate to the number of new cells formation. This pathological condition will ultimately reduce the function of the heart muscles. Platelet-rich plasma (PRP) in the last decade has been attracting attention regarding its role in cell regeneration. The content of cytokines and growth factors contained in PRP such as Platelet-Derived Growth Factor (PDGF), Transforming Growth Factor Beta 1 (TGF-Β1), Epidermal Growth Factor (EGF), Vascular Endothelial Growth Factor (VEGF), Basic Fibroblast Growth Factor (bFGF) and others are known to be involved in the migration, proliferation, and differentiation of various cell types and to induce post-ischemic angiogenesis. This review aims to analyze and investigate the benefits of PRP therapy in myocardial infarction. Recent literatures regarding the use of PRP in myocardial infarction was collected by searching PubMed and Google Scholar databases with the keywords of “Platelet-rich plasma”, “Myocardial Infarction”, “Reperfusion”, and “Angiogenesis”. The researches used was published between January 2011 and December 2022. Based on the results, Platelet-rich Plasma (PRP) is considered capable of accelerating angiogenesis, mitogenesis, protect cells from free radicals, reduce infarct area and scar tissue in myocardial infarction. PRP can also improve cardiac function in post myocardial infarction by increasing ejection fraction. In addition, PRP can also reduce treatment costs due to the risk of myocardial infarction complications such as bleeding and infection.
Note: This article has supplementary file(s).
Article Metrics:
Last update:
The Authors submitting a manuscript do so on the understanding that if accepted for publication, copyright of the article shall be assigned to Journal of Biomedicine and Translational Research Diponegoro University as publisher of the journal.
Copyright encompasses non-exclusive rights to reproduce and deliver the article in all form and media, including reprints, photographs, microfilms and any other similar reproductions, as well as translations.
Journal of Biomedicine and Translational Research Diponegoro University, the Editors and the Advisory International Editorial Board make every effort to ensure that no wrong or misleading data, opinions or statements be published in the journal. In any way, the contents of the articles and advertisements published in the Journal of Biomedicine and Translational Research Diponegoro University (JBTR) are sole and exclusive responsibility of their respective authors and advertisers.
The Copyright Transfer Form can be downloaded here: [Copyright Transfer Form JBTR]
The copyright form should be signed originally and send to the Editorial Office in the form of original mail, scanned document or fax : Journal of Biomedicine and Translational Research Faculty of Medicine, Diponegoro UniversityJl. Prof. Soedarto, Kampus UNDIP Tembalang, Semarang, Central Java, Indonesia 50275, Telp.: +62-24-8454714, Fax.: +62-24-8454714Email: jbtr@fk.undip.ac.id
JBTR by https://ejournal2.undip.ac.id/index.php/jbtr is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
View My Stats